Martin Chevarin

Mr. Martin Chevarin

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
23 June 2019 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
ABAnge-Line Bruel
Ange-Line Bruel
SNSophie Nambot
Sophie Nambot
VQVirginie Quéré
Virginie Quéré
AVAntonio Vitobello
Antonio Vitobello
JTJulien Thevenon
Julien Thevenon
CTChristel Thauvin-Robinet
Christel Thauvin-Robinet
In clinical exome sequencing (cES), the American College of Medical Genetics and Genomics recommends limiting variant interpretation to established human-disease genes. The diagnostic yield of cES in intellectual disability and/or multiple congenital anomalies (ID/MCA) is currently about 30%. Though the results may seem acceptable for rare diseases, they mean that 70% of affected individuals remain genetically undiagnosed. Further analysis extended to all mutated genes in a research environment is a valuable strategy for improving diagnostic yields. This study presents the results of systematic research reanalysis of negative cES in a cohort of 313 individuals with ID/MCA. We identified 17 new genes not related to human disease, implicated 22 non-OMIM disease-causing genes recently or previously rarely related to disease, and described 1 new phenotype associated with a known gene. Twenty-six candidate genes were identified and are waiting for future recurrence. Overall, we diagnose 15% of the individuals with initial negative cES, increasing the diagnostic yield from 30% to more than 40% (or 46% if strong candidate genes are considered). This study demonstrates the power of such extended research reanalysis to increase scientific knowledge of rare diseases. These novel findings can then be applied in the field of diagnostics.

31 January 2020 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
CSCAUSES Study
CAUSES Study
SNSophie Nambot
Sophie Nambot
LFLaurence Faivre
Laurence Faivre
GMGhayda Mirzaa
Ghayda Mirzaa
JTJulien Thevenon
Julien Thevenon
CTChristel Thauvin-Robinet
Christel Thauvin-Robinet
TBR1, a T-box transcription factor expressed in the cerebral cortex, regulates the expression of several candidate genes for autism spectrum disorders (ASD). Although TBR1 has been reported as a high-confidence risk gene for ASD and intellectual disability (ID) in functional and clinical reports since 2011, TBR1 has only recently been recorded as a human disease gene in the OMIM database. Currently, the neurodevelopmental disorders and structural brain anomalies associated with TBR1 variants are not well characterized. Through international data sharing, we collected data from 25 unreported individuals and compared them with data from the literature. We evaluated structural brain anomalies in seven individuals by analysis of MRI images, and compared these with anomalies observed in TBR1 mutant mice. The phenotype included ID in all individuals, associated to autistic traits in 76% of them. No recognizable facial phenotype could be identified. MRI analysis revealed a reduction of the anterior commissure and suggested new features including dysplastic hippocampus and subtle neocortical dysgenesis. This report supports the role of TBR1 in ID associated with autistic traits and suggests new structural brain malformations in humans. We hope this work will help geneticists to interpret TBR1 variants and diagnose ASD probands.

1 November 2019 in Genetics in Medicine
Verified
Journal Article
Closed access
PDF file
FLFrançois Lecoquierre
François Lecoquierre
YDYannis Duffourd
Yannis Duffourd
AVAntonio Vitobello
Antonio Vitobello
ABAnge-Line Bruel
Ange-Line Bruel
BUBenoit Urteaga
Benoit Urteaga
CTChristel Thauvin-Robinet
Christel Thauvin-Robinet

24 April 2019 in European Journal of Human Genetics
Verified
Journal Article
Closed access
PDF file
CTChristel Thauvin-Robinet
Christel Thauvin-Robinet
JTJulien Thevenon
Julien Thevenon
SNSophie Nambot
Sophie Nambot
JDJulian Delanne
Julian Delanne
PKPaul Kuentz
Paul Kuentz
LFLaurence Faivre
Laurence Faivre

18 August 2022 in Pathogens
Verified
Journal Article
Open access
PDF file
EBEloïse BAILLY
Eloïse BAILLY
SVStéphane Valot
Stéphane Valot
AVAnne Vincent
Anne Vincent
YDYannis Duffourd
Yannis Duffourd
NGNadège Grangier
Nadège Grangier
FDFrederic Dalle
Frederic Dalle
Background. Nowadays, most of the C. parvum and C. hominis epidemiological studies are based on gp60 gene subtyping using the Sanger sequencing (SgS) method. Unfortunately, SgS presents the limitation of being unable to detect mixed infections. Next-Generation Sequencing (NGS) seems to be an interesting solution to overcome SgS limits. Thus, the aim of our study was to (i) evaluate the reliability of NGS as a molecular typing tool for cryptosporidiosis, (ii) investigate the genetic diversity of the parasite and the frequency of mixed infections, (iii) assess NGS usefulness in Cryptosporidium sp. outbreak investigations, and (iv) assess an interpretation threshold of sequencing data. Methods. 108 DNA extracts from positive samples were sequenced by NGS. Among them, two samples were used to validate the reliability of the subtyping obtained by NGS and its capacity to detect DNA mixtures. In parallel, 106 samples from French outbreaks were used to expose NGS to epidemic samples. Results. NGS proved suitable for Cryptosporidium sp. subtyping at the gp60 gene locus, bringing more genetic information compared to SgS, especially by working on many samples simultaneously and detecting more diversity. Conclusions. This study confirms the usefulness of NGS applied to C. hominis and C. parvum epidemiological studies, especially aimed at detecting minority variants.

5 December 2020 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
AGAurore Garde
Aurore Garde
JCJenny Cornaton
Jenny Cornaton
ASArthur Sorlin
Arthur Sorlin
SMSébastien Moutton
Sébastien Moutton
CNClaire Nicolas
Claire Nicolas
LFLaurence Faivre
Laurence Faivre